Arbor Vita Corporation Receives Phase II SBIR To Commercialize Cervical Cancer Diagnostic
Published: Sep 20, 2006
SUNNYVALE, Calif., Sept. 20 /PRNewswire/ -- Arbor Vita Corporation, a biotechnology company, today announced that the National Institutes of Health (NIH) has awarded Arbor Vita approximately $900,000 to develop and commercialize an in vitro diagnostic test for cervical pre-cancer and cancer. The Phase II Small Business Innovation Research (SBIR) grant will fund the company's test based on detection of the HPV-E6 oncoprotein. The E6 protein has been identified as a cancer specific marker produced by HPV that is associated with progression to cancer.